Gene One Life Science, VGXI Ordered to Pay USD 80.42 Million in Inovio Lawsuit

By Public Technologies
  • Gene One Life Science and subsidiary VGXI face a USD 80.42 million default judgment in favor of Inovio Pharmaceuticals.
  • Pennsylvania’s Montgomery County court issued the October 19, 2026 ruling over alleged breaches of a DNA plasmid supply agreement and technology-transfer obligations.
  • The award comprises USD 61.75 million in damages and USD 18.67 million in attorneys’ fees and expenses.
  • The judgment totals KRW 106.46 billion, equivalent to 260.3% of the company’s equity.
  • The company and subsidiary plan to seek to vacate the judgment and pursue an appeal, citing procedural and substantive objections.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021800687), on October 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.